Last reviewed · How we verify
LAMA/LABA
LAMA/LABA is a dual bronchodilator combining a long-acting muscarinic antagonist and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow.
LAMA/LABA is a dual bronchodilator combining a long-acting muscarinic antagonist and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (in some LAMA/LABA formulations).
At a glance
| Generic name | LAMA/LABA |
|---|---|
| Also known as | GSK573719+GW642444, umeclidinium (GSK573719) / vilanterol (GW642444), Anoro ELLIPTA |
| Sponsor | Queen's University |
| Drug class | LAMA/LABA combination bronchodilator |
| Target | Muscarinic M3 receptor and beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
LAMAs block muscarinic M3 receptors on airway smooth muscle, reducing acetylcholine-induced bronchoconstriction. LABAs activate beta-2 adrenergic receptors, increasing cAMP and promoting smooth muscle relaxation. The combination provides complementary bronchodilation through two distinct pathways, improving lung function and reducing symptoms in obstructive airway disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (in some LAMA/LABA formulations)
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nasopharyngitis
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PHASE3)
- Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
- Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). (PHASE3)
- Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
- A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils (PHASE2)
- Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAMA/LABA CI brief — competitive landscape report
- LAMA/LABA updates RSS · CI watch RSS
- Queen's University portfolio CI